Company / Return on Assets (ROA)
MoonLake Immunotherapeutics Return on Assets (ROA) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-53.6%
FY2025
5-year range
-65.0% / -6.8%
FY2021-FY2025
Trend
-115.2%
vs FY2024
Sector context
#182 of 213
Health Care
What the data says
MoonLake Immunotherapeutics's return on assets (roa) of -53.6% is lower than 85% of companies in the Health Care sector (FY2025). Declined from -6.8% to -53.6% over the past 2 years.
Based on SEC 10-K filings.
-53.6% in FY2025 with a 5-year CAGR of -53.5%.
Declined from -6.8% to -53.6% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +11.5pp
- 5-Year Change
- -53.5pp
- 10-Year Change
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 213This company -53.6% Sector average -24.1%
▼
-121.9% below sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) decreased 115.2% year-over-year.
- Currently 29.4pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2020.
- Lowest return on assets (roa) in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -53.6% | -115.2% |
| FY2024 | -24.9% | -263.9% |
| FY2023 | -6.8% | +89.5% |
| FY2022 | -65.0% | - |
| FY2021 | - | - |
| FY2020 | -0.1% | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026